12:00 AM
Dec 19, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Results

PSI-7977: Phase IIb amended

Pharmasset will discontinue all treatment arms containing PSI-938 in the double-blind, placebo-controlled, international Phase IIb QUANTUM trial in about 450 treatment-naïve patients after detecting laboratory abnormalities associated with liver function in patients receiving a once-daily 300 mg dose of the compound during a routine safety analysis. The trial was evaluating PSI-938 alone or in combination with PSI-7977 with and without ribavirin for 12 or 24 weeks. The remaining...

Read the full 328 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >